| Literature DB >> 36231212 |
Paula García-Ríos1, María Pilar Pecci-Lloret1, Ricardo Elías Oñate-Sánchez1.
Abstract
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that is characterized by clinical heterogeneity and irregularities in its course. The etiology and pathogenesis of this pathology are not well-understood, so there is difficulty in establishing a diagnosis and treatment plan with certainty. The aim of this systematic review is to present a qualitative synthesis of studies referring to the oral manifestations of systemic lupus erythematosus (SLE). This systematic review was performed following the PRISMA guideline. On this basis, a search for articles was performed in the PubMed, Web of Science, and Scopus databases on 19 November 2021 and updated on 15 February 2022. We chose articles published between 2012 and 2022 that analyzed the oral manifestations of SLE patients. The quality of all these studies was analyzed following the STROBE scale. A total of 15 articles were included in this study after selection. The selected articles were cross-sectional, case-control, and cohort studies. The most frequently associated oral manifestations with SLE were oral ulcers, hyposalivation, pigmentations, glossodynia, cleft tongue, cheilitis, arthritis, and secondary Sjögren's syndrome. However, despite the importance of the perception of these oral manifestations in the early diagnosis of SLE, there are still not enough studies about them.Entities:
Keywords: oral manifestations; oral ulcers; systemic lupus erythematosus
Mesh:
Year: 2022 PMID: 36231212 PMCID: PMC9565705 DOI: 10.3390/ijerph191911910
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Search strategy.
| Base of | Search Field | Results |
|---|---|---|
| Medline (PubMed) | (1) “Systemic lupus erythematosus” OR “lupus erythematosus disseminates” OR “Libman–Sacks disease” OR “disease, Libman–Sacks” OR “Libman–Sacks disease”. | 73,780 |
| (2) “Oral manifestations” OR “manifestation, oral”. | 4311 | |
|
|
| |
| Web of Science | (1) “Systemic lupus erythematosus” OR “lupus erythematosus disseminatus” OR “Libman–Sacks disease” OR “disease, Libman–Sacks” OR “Libman–Sacks disease”. | 75,149 |
| (2) “Oral manifestations” OR “manifestation, oral” OR “manifestation, oral”. | 1826 | |
|
|
| |
| SCOPUS | (1) “Systemic lupus erythematosus” OR “lupus erythematosus disseminatus” OR “Libman–Sacks disease” OR “disease, Libman–Sacks” OR “Libman–Sacks disease”. | 95,177 |
| (2) “Oral manifestations” OR “manifestation, oral” OR “manifestation, oral”. | 4937 | |
|
|
|
Figure 1Systematic flow diagram.
Description of the differentiated variables.
| Author | Year | Type of Study | Most Prevalent Manifestations | Most Frequent Locations | Associated Conditions |
|---|---|---|---|---|---|
| Zakeri et al. [ | 2012 | Cross-sectional | Erosion, hyperkeratosis, oral pigmentation, and oral ulcers | Hard palate, soft palate, and lower lip | - |
| Ali et al. [ | 2020 | Case–control | Oral ulcers | - | Haplotype C of CD34 gene polymorphism associated with oral ulcers. |
| Aterido et al. [ | 2017 | Cohort | Oral ulcers | - | VEGF pathway, increased SLE activity, and worse prognosis associated with oral ulcers. |
| Li et al. [ | 2014 | Cohort | - | - | APL antibody and a lower prevalence of oral ulcers. |
| Leite et al. [ | 2015 | Cross-sectional | More than 75% with dry mouth | - | Disease activity, medication, 27+ years associated with hyposalivation. |
| Manzano et al. [ | 2021 | Case–control | Decreased salivary flow rate | - | Negative impact on quality of life and mental health related to xerostomia. |
| Chacon et al. [ | 2020 | Cohort | Hyperpigmented macules due to medication | Hard palate, cheeks and tongue | - |
| Aurlene et al. [ | 2020 | Cross-sectional | Oral ulcer | Hard palate | Patient age and gingival bleeding. Disease activity and decayed, missing teeth, gingival bleeding, increased probing depth, and oral mucosal lesions. |
| Hammoudeh et al. [ | 2018 | Pilot study | Oral ulcers | Hard palate | Increased prevalence of candidiasis, infections, and periodontitis in SLE patients. |
| Crincoli et al. [ | 2020 | Case–control | Oral ulcers, glossodynia, fissured tongue, cheilitis | Hard palate, buccal mucosa, and lips | Hyposalivation, TMJ, and muscle involvement with SLE. |
| Fonseca et al. [ | 2018 | Cross-sectional | Oral ulceration, arthritis, and secondary Sjögren’s syndrome | - | Ulcers and juvenile SLE. Arthritis and Sjögren’s disease, and adult SLE. |
| Choi et al. [ | 2015 | Cross-sectional | Oral ulcers and Sjögren’s syndrome | - | Ulcers and juvenile SLE. Sjögren’s disease and adult SLE. |
| Artim-Esen et al. [ | 2017 | Cohort | Oral ulcers | - | Most common oral ulcers and viral infections in juvenile-onset SLE. |
| Lee et al. [ | 2013 | Cohort | Malar rash, arthritis and oral ulceration | - | More common in pediatric-onset SLE. |
| Novak et al. [ | 2018 | Cohort | Oral ulcers | Palate | Most frequent oral ulcers in patients with long interval to diagnosis. |
Oral signs and symptoms and their significant association.
| Author | Parameter 1 | Parameter 2 | Significance Level |
|---|---|---|---|
| Zakeri et al. [ | Prevalence of SLE | 1. Age | 1. Not significant, |
| Ali et al. [ | CD34 gene haplotypes | 1. Distribution A, D–H | 1. Significant, |
| Aterido et al. [ | Via VEGF | Presence of oral ulcers | Significant, |
| Li et al. [ | 1. APL antibody | 1. Lower prevalence of oral ulcers | 1. Significant, |
| Leite et al. [ | Severity of hyposalivation | 1. SLE activity | 1. Significant, |
| Manzano et al. [ | LES | Lower salivary flow stimulated and not | Significant, |
| Chacon et al. [ | Hyperpigmented macules | Antimalarials | 1. Not significant |
| Aurlene et al. [ | 1. Age | 1. Gingival bleeding and decayed and missing teeth | 1. Significant, |
| Hammoudeh et al. [ | SLE > 8 years | Periodontitis | Significant, |
| Crincoli et al. [ | LES | 1. Headache in the temples and difficulty opening the mouth | 1. Significant, |
| Fonseca et al. [ | Juvenile LES | Oral ulcers and malar rash | Significant, |
| Adult SLE | Arthritis | Significant, | |
| Choi et al. [ | Juvenile LES | Oral ulcers | Significant, |
| Late SLE | Sjögren’s syndrome | Significant, | |
| Artim-Esen et al. [ | Juvenile LES | Oral ulcers | Significant, |
| Lee et al. [ | Sex | Oral ulcers | Not significant, |
| Novak et al. [ | SLE > 3 months after diagnosis | Oral ulcers | Significant, |
Figure 2Summary of systematic lupus erythematosus’ oral manifestations.
Quality analysis results.
| Zakeri et al. | Ali et al. | Aterido et al. | Li et al. | Leite et al. | Manzano et al. | Chacon et al. | Aurlene et al. | Hammoudeh et al. | Crincoli et al. 2020 [ | Fonseca et al. | Choi et al. | Artim-Esen et al. 2017 [ | Lee et al. | Novak et al. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ |
| 2 | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | 🗶 |
| 3 | ✔ | 🗶 | ✔ | 🗶 | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ |
| 4 | ✔ | ✔ | ✔ | 🗶 | ✔ | ✔ | 🗶 | 🗶 | 🗶 | ✔ | ✔ | 🗶 | ✔ | ✔ | ✔ |
| 5 | 🗶 | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ |
| 6 | 🗶 | 🗶 | ✔ | ✔ | ✔ | ✔ | ✔ | 🗶 | 🗶 | ✔ | 🗶 | ✔ | ✔ | ✔ | ✔ |
| 7 | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | 🗶 | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ |
| 8 | 🗶 | 🗶 | 🗶 | 🗶 | ✔ | ✔ | 🗶 | 🗶 | 🗶 | ✔ | 🗶 | 🗶 | 🗶 | ✔ | 🗶 |
| 9 | 🗶 | 🗶 | 🗶 | 🗶 | 🗶 | ✔ | 🗶 | ✔ | 🗶 | 🗶 | 🗶 | 🗶 | 🗶 | 🗶 | 🗶 |
| 10 | ✔ | 🗶 | ✔ | ✔ | ✔ | 🗶 | ✔ | ✔ | ✔ | ✔ | 🗶 | ✔ | ✔ | ✔ | ✔ |
| 11 | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | 🗶 | 🗶 | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ |
| 12 | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ |
| 13 | ✔ | 🗶 | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ |
| 14 | ✔ | 🗶 | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ |
| 15 | 🗶 | 🗶 | ✔ | ✔ | ✔ | ✔ | 🗶 | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ |
| 16 | 🗶 | ✔ | 🗶 | ✔ | 🗶 | ✔ | 🗶 | ✔ | ✔ | 🗶 | ✔ | 🗶 | 🗶 | 🗶 | ✔ |
| 17 | ✔ | ✔ | 🗶 | ✔ | 🗶 | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | 🗶 | 🗶 |
| 18 | ✔ | 🗶 | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | 🗶 |
| 19 | ✔ | 🗶 | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | 🗶 | 🗶 | ✔ | ✔ | ✔ | ✔ | ✔ |
| 20 | ✔ | ✔ | ✔ | 🗶 | ✔ | 🗶 | 🗶 | ✔ | 🗶 | ✔ | ✔ | ✔ | 🗶 | ✔ | 🗶 |
| 21 | ✔ | 🗶 | ✔ | 🗶 | ✔ | ✔ | ✔ | ✔ | 🗶 | ✔ | ✔ | ✔ | 🗶 | ✔ | 🗶 |
| 22 | ✔ | 🗶 | ✔ | ✔ | 🗶 | ✔ | 🗶 | 🗶 | 🗶 | 🗶 | 🗶 | ✔ | 🗶 | 🗶 | ✔ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* Mod: Moderate.
Figure 3Distribution by year of publication.
Figure 4Distribution by country of publication.
Figure 5Distribution by journal of publication.